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1. Introduction 
Down Syndrome (DS) is one of the most common genetic disorders to date, occurring in 1 
out of every 800-1000 live births (Egan et al. 2004; Roizen & Patterson, 2003; Stoll et al. 1990). 
DS patients often display several developmental and cognitive deficiencies. Common 
phenotypes of DS patients include congenital heart disease, dysmorphic physical features, 
and early-onset Alzheimer’s disease (AD). Since the discovery in 1959 that DS occurs from 
an extra copy of human chromosome 21 (hChr21) (Lejeune J, Gautier & Turpin, 1959), 
questions arose whether a 1.5-fold increase in a gene or set of genes were responsible for the 
phenotypes associated with DS. Sequence analysis of hChr21 indentified over 225 genes 
and/or predicted genes (Hattori et al. 2000). With the recent advances in sequencing, the 
gene content of hChr21 is now estimated to exceed 300 genes (Roizen & Patterson, 2003). 
While typically characterized by complete trisomy of hChr21, several DS cases, however, 
demonstrate that partial trisomy of hChr21 is enough to elicit the phenotypes associated 
with DS (Stoll et al. 1990), hence arising the concept of a Down Syndrome Critical Region 
(DSCR). The DSCR theory suggests that enhanced expression of a few genes located in this 
critical chromosomal region (between markers D21S17 and D21S55 (Delabar et al. 1993; 
Korenberg et al. 1994)) are responsible for some, if not all, of the features of DS. Olson LE et 
al show, however, that triplication of this region alone is not enough to fully manifest the 
phenotypes associated with DS (Olson et al. 2004; Olson et al. 2007). These findings 
contradict the longstanding DSCR theory, indicating that the genetic instability seen with 
hChr21 triplication is not merely from excess gene expression. Rather, the functional 
interactions occurring within a set of overexpressed genes may explain the various 
phenotypes observed in DS.  
Many of the triplicate genes on hChr21 are implicated in several diseases. Cohorts of genes, 
interestingly, have been associated with pathologies that appear to be more common for DS 
individuals. A group of at least 16 genes on hChr21 have been correlated with a role in 
energy and reactive oxygen species (ROS) metabolism (Roizen & Patterson, 2003). Several 
studies have linked mitochondrial dysfunction and metabolic disorders with DS (Arbuzova, 
Hutchin & Cuckle, 2002). In vitro, DS neurons were observed to have 3- to 4-fold increases in 
reactive oxygen species compared to control cells, with elevated rates of consequent cell 
apoptosis (Busciglio & Yankner, 1995). Degeneration of DS neurons was rescued by 
administration of free-radical scavengers, suggesting DS neurons are unable to efficiently 
metabolize ROS. DS patients are also evidenced to have increased mitochondrial superoxide 
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production compared to control groups (Capone et al. 2002). In addition, Busciglio J et al. 
show altered processing of the amyloid precursor protein (APP) in DS astrocytes and 
neurons (Busciglio et al. 2002). Elevated levels of APP, a gene also located on hChr21, have 
been associated with AD progression. Given that DS patients invariably display the 
characteristic plaques and tangles suggestive of AD (Hardy & Selkoe, 2002), this 1.5-fold 
increase in particular hChr21-located genes may explain the metabolic-related diseases 
associated with DS patients.  
Another cohort of at least 10 genes located on hChr21 have been demonstrated to influence 
the central nervous system (CNS), and may hence play a role in the neuropathogenesis of 
DS (Capone, 2001). Considering the major phenotypes of DS patients include altered brain 
development, neuronal loss, and Alzheimer’s-like neuropathology, the identification of 
CNS-related genes is not surprising. As demonstrated by these two gene clusters, 
phenotypic outcome is dependent not only on genotype but also on successive protein 
interactions. It is therefore possible that additional sets of genes, when in excess as a result 
of trisomy hChr21, lead to the manifestation of other DS-related pathologies, such as 
vascular-related pathologies. 
2. Clinical observations and chapter overview 
While developmental and behavioral disorders have been extensively studied in adults with 
DS, relatively little is known regarding their propensity to vascular-related diseases. Several 
intriguing clinical observations relating to the vasculature have been reported amongst DS 
patients over the last several decades. Unlike the aforementioned developmental deficits of 
DS individuals, DS patients appear to have a unique advantage in the context of several 
vascular pathologies.  
2.1 Cancer incidence in DS patients 
While adults with DS have been shown to have a higher incidence of leukemia compared to 
the  general public, the risk of solid tumors appear to be strikingly low in individuals with 
DS (Hasle, Clemmensen & Mikkelsen, 2000). A population-based study on causes of 
mortality in over 17,000 DS patients showed a significant lack of malignant neoplasms as a 
cause of death (Yang, Rasmussen & Friedman, 2002). These findings suggest that 
individuals with DS express possible tumor-suppressor genes on hChr21, such that trisomy 
of a set of genes results in an antineoplastic effect on solid tumors. It is possible that these set 
of genes modulate a common biological mechanism that is critical for tumorigenesis and/or 
cancer progression. 
2.2 Atherosclerosis in DS patients 
A post-mortem, observational study published in 1977 found that 40-66 year old patients 
with DS displayed an almost complete absence of atherosclerotic plaque formation in 
arteries, compared to those without DS (Murdoch et al. 1977). Additional population studies 
in DS patients have found consistent results (Draheim, Geijer & Dengel, 2010; Yla-Herttuala 
et al. 1989), leading one to speculate that an unidentified factor(s) specific to DS patients 
explains the near absence of atherosclerotic plaque formation. Considering the vascular 
similarities between tumorigenesis and atherosclerosis, it is possible these events are driven 
by a shared molecular mechanism. 
www.intechopen.com
 
Down Syndrome and Vascular Disease: DSCR1 and NFAT Signaling 
 
139 
2.3 Other vascular pathologies in DS patients 
Studies focusing on vascular tone show that DS patients have extremely low percentages of 
hypertension (Kerins et al. 2008). Significant decreases in both systolic and diastolic pressures 
were observed in DS patients when compared to reference populations (Morrison et al. 1996; 
Richards & Enver, 1979). Low blood pressures have also been observed in Alzheimer’s disease 
(AD) (Burke et al. 1994; Landin et al. 1993), suggesting the mechanisms driving AD contribute 
to the observed hypotensive tendencies of DS patients. The already mentioned propensity for 
DS patients to develop AD, in addition to blood pressure levels similar to that of AD patients, 
strongly suggests a shared genetic contribution(s) of hChr21-located genes.  
The observed decrease in solid tumor growth, lack of atherosclerotic plaque formation, and 
hypotensive nature of DS adults indicates onset of these vascular disorders may share an 
underlying molecular mechanism. This chapter will aim to discuss the observed differences 
in the vasculature of DS patients based on current literature to date. As of now, there is no 
concrete evidence distinguishing DS patients from non-DS patients on a genetic level 
concerning vascular anomalies. Correlative studies, however, suggest DS individuals 
harness a genetic advantage in regard to vascular health and disease. 
3. Tumorigenesis in Down Syndrome 
The molecular mechanisms underlying oncogenesis are undoubtedly one of the most 
intricate processes to date. Accumulation of multiple genomic mutations leads to the 
dysregulation of cell signaling pathways that are critical for controlling basic cellular 
functions including cell growth, survival, and cell fate. The extensive cross-talk between 
various signaling cascades highlights the sophisticated communication that transpires 
during cancer development and progression.  
3.1 Calcium/calcineurin/NFAT signaling 
Calcium (Ca2+) fluxes are involved in multiple cell processes such as cell metabolism, 
membrane transport, cell permeability, and apoptosis. Changes in intracellular Ca2+ levels 
affect downstream gene expression and cell function through various mechanisms. In 
particular, intracellular Ca2+ concentrations often regulate kinase and phosphatase activity 
through the Ca2+-binding protein, calmodulin (CaM). Increases in intracellular Ca2+ have 
been demonstrated in various cell types to activate the Ca2+/CaM-dependent serine-
threonine protein phosphatase, calcineurin (Cn). The Cn pathway is critical for the 
transduction of many extracellular, adaptive stimuli. Activated Cn subsequently 
dephosphorylates target proteins, including the nuclear factor of activated T-cells (NFATc1-
c4) family of transcription factors (Figure 1). The NFAT family was originally identified in 
lymphocytes for its role in cytokine gene expression. While first identified in immune cells, 
recent findings show NFAT proteins are ubiquitously expressed. NFAT at the basal state are 
localized to the cytoplasm in an inactive form, with more than 20 identified phosphorylation 
sites (Okamura et al. 2000). CaM/Cn-mediated dephosphorylation of NFAT promotes 
nuclear translocation and target gene transcription (Figure 1). As downstream effectors of 
the Cn signaling pathway, NFAT-dependent gene transcription influences a range of 
cellular functions, including endothelial cell migration (Minami et al. 2004), skeletal muscle 
differentiation (Rothermel et al. 2000), cardiac valve development (Lange, Molkentin & 
Yutzey, 2004), and vascular smooth muscle cell adaptation (Crabtree & Olson, 2002; 
Horsley& Pavlath, 2002; Lee et al. 2010).  
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Fig. 1. The Cn/NFAT signaling pathway. calmodulin (CaM), calcineurin (Cn), cyclosporin A 
(CsA) (adapted from Viola, J.B.P., 2005) 
Given the versatility of NFAT activation, it is not surprising that solid tumors and 
haematological malignances are correlated with overexpression of NFATc isoforms. For 
example, pancreatic carcinomas display elevated levels of NFATc1 for transcriptional 
activation of the c-myc oncogene (Buchholz et al. 2006). Studies using human breast 
carcinoma cell lines also show NFATc2 expression promotes carcinoma migration and 
invasion (Jauliac et al. 2002). The increased NFATc activity in malignant cells suggests 
activation of downstream NFATc targets is critical for tumor progression. Cyclooxygenase-2 
(COX2/PTGS2) has been reported by several groups as an NFAT-dependent gene in non-
lymphoid tissues, including endothelial cells (Hernandez et al. 2001), mesangial cells 
(Sugimoto et al. 2001), and vascular smooth muscle cells (Pritchard, Jr. et al. 1994). As an 
enzyme involved in prostaglandin formation, COX2 expression plays an important role in 
cell survival and angiogenesis. A gain-of-function approach shows that forced 
overexpression of COX2 alone is enough to induce mammary gland tumorigenesis (Liu et al. 
2001). On the converse, inhibition of COX2 significantly reduces colon tumor incidence and 
multiplicity in a dose-dependent manner (Reddy et al. 2000). These findings strongly 
support the notion that tumor growth/invasion necessitates an abundance of COX2 levels. 
The increased expression of COX2 in a multitude of cancer lines (i.e. gastric, esophageal, 
breast, bladder, cervical, colorectal, endometrial (Brown & DuBois, 2005; Duque, Fresno & 
Iniguez, 2005b)) have thus launched the production of several COX2 inhibitors with 
therapeutic potential. It is, however, important to note the importance of COX2 in other cell 
types. Unlike the constitutively expressed COX1 isoform, COX2 expression occurs in a 
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limited number of cell types, primarily in response to cytokines, inflammatory mediators, 
and tissue damage (Lipsky et al. 2000). The inducible nature of COX2 activation results in 
prostaglandin formation, including prostacyclin, a vasodilator and a potent inhibitor of 
platelet aggregation. Prostacylin formation in vascular endothelial cells thus provides a 
mechanism by which the thrombotic response in platelet activation can be regulated (Rudic 
et al. 2005). Hence, COX2 expression is necessary to maintain vascular health. While COX2-
selective inhibitors may attenuate tumor angiogenesis, COX2 antagonists will undoubtedly 
shift eicosanoid balance toward a prothrombotic state, promoting the risk for cardiovascular 
events (Mukherjee, Nissen & Topol, 2001). Targeting other proteins involved in Cn/NFAT 
signaling aside from COX2 may yield similar anti-neoplastic results. 
Tumor survival and growth is highly-dependent on a vascular system for delivery of 
essential nutrients and oxygen. A tumor’s vasculature also provides a mechanism by which 
aberrant cells can disseminate and metastasize to other organs. Without a constant blood 
supply, tumor volumes tend to remain 1-2mm3 in size (Brown & DuBois, 2005). 
Angiogenesis is a multi-step process that involves migration, proliferation, and 
differentiation of both endothelial and vascular smooth muscle cells for generation of 
mature vessels. Tumor cells can facilitate an ‘angiogeneic switch’ by altering gene 
transcription and the surrounding microenvironment. Somatic mutations of various proto-
oncogenes and/or tumor suppressor genes offset the balance between activators and 
inhibitors of angiogenesis, ultimately favoring angiogenic activity (Hanahan & Weinberg, 
2000). Pro-angiogeneic gene expression is induced by a number of physiological stimuli, 
such as hypoxia. Cells in hypoxic conditions produce the hypoxia-inducible factor (HIF) 
transcription factor, where expression of HIF-1 results in Vascular Endothelial Growth 
Factor (VEGF) transcription (Forsythe et al. 1996). VEGF, a major stimulator of angiogenesis, 
is a potent endothelial mitogen involved in both physiological and pathological blood vessel 
formation. VEGF is critical for proper embryonic vasculogenesis, as even heterozygous 
VEGF-deficient mice display abnormal blood vessel formation and consequent embryonic 
lethality (Carmeliet et al. 1996). While necessary for proper blood vessel development, excess 
VEGF can result in pathological angiogenesis. HIF-1-mediated VEGF expression and 
activation of other angiogenesis-related genes exemplifies the adaptive responses seen in 
tumor survival and growth. VEGF has also been demonstrated to induce COX2 expression 
in a Cn/NFAT-dependent manner (Duque, Fresno & Iniguez, 2005c). As previously 
mentioned, COX2 expression is critical for tumor cell migration and tube formation. The 
emerging role of NFAT signaling in oncogenesis is further highlighted, as pharmacological 
inhibition of NFAT blocks VEGF-stimulated COX2 expression and subsequent cell 
proliferation and/or angiogenesis both in vitro and in vivo (Hernandez et al. 2001). These 
results imply activation of Cn/NFAT signaling is required for the formation of new blood 
vessels, where regulation of angiogenesis is dependent on a local balance between 
angiogenic factors and inhibitors. The identification of Cn/NFAT activators and 
downstream NFAT target genes in the last few decades has therefore helped elucidate the 
biological mechanisms underlying oncogenesis. 
3.2 DSCR1 in cancer progression 
Cancer incidence for all solid tumors and malignancies have been shown in multiple DS 
population studies to be significantly lower in DS patients compared to control groups 
(Hasle et al. 2000; Yang et al. 2002). Interestingly, a large focus has been placed on the role of 
the Down Syndrome Candidate Region 1 (DSCR1/RCAN1/MCIP1) gene in cancer 
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progression. Located on hChr21, DSCR1 has been demonstrated as a negative feedback 
regulator of Cn/NFAT signaling through physical binding to the catalytic subunit of Cn 
(Fuentes et al. 2000) (Figure 1). In endothelial cells, VEGF and thrombin stimulation 
dramatically upregulate DSCR1 expression in a Cn/NFAT dependent manner (Iizuka et al. 
2004; Minami et al. 2004). Several studies in endothelial cells have shown that DSCR1 
overexpression inhibits NFAT transcriptional activity, suppresses NFAT nuclear 
accumulation, and attenuates NFAT-dependent inflammatory marker gene expression, such 
as COX2 (Hesser et al. 2004; Yao & Duh, 2004). Studies also show DSCR1 overexpression in 
endothelial cells reduces vascular density in matrigel plugs in vitro and in tumor growth in 
mice (Minami et al. 2004). Lastly, functional data indicate constitutive expression of DSCR1 
impairs endothelial cell proliferation and tube formation (Minami et al. 2004). Taken 
together, VEGF and thrombin-mediated endothelial cell proliferation/vascularization 
induces expression of DSCR1 as a mechanism to negatively regulate the angiogenic 
processes.  
Researchers have attempted to explain the lack of tumorigenesis in the DS population 
through use of genetically modified mice. Comparative mapping between mice and humans 
identify that hChr21 is genetically homologous to mouse chromosome 16 (mChr16) (Reeves 
& Citron, 1994). Thus, mice exhibiting trisomy of mChr16 (Ts16) were originally developed 
to study DS. Ts16 mice, however, die in utero and therefore pose as a limitation. In addition, 
several genes located on mChr16 are found on human chromosomes other than hChr21. The 
observed embryonic lethality as well as gene dosage imbalances resulted in generation of 
the Ts65Dn mouse (Reeves et al. 1995). The Ts65Dn mouse model reflects partial trisomy of 
hChr21, where mice have been reported to display a variety of phenotypes, including 
behavioral abnormalities consistent with DS (Reeves et al. 1995). Ts65Dn mice are now 
widely used to study DS at all stages of development.  
A recent publication highlights the suppression of tumor growth seen in DS individuals 
using two different models: 1) the Ts65Dn mouse and 2) a DSCR1-transgenic mouse. 
Ts65Dn mice possess extra genetic information including the DSCR1 gene – Ts65Dn mice 
exhibit a 1.7-fold increase in DSCR1 protein expression compared to diploid controls (Baek 
et al. 2009). Baek KH et al demonstrate that both lung carcinoma and melanoma cell growth 
was significantly suppressed in Ts65Dn mice, when compared to control groups (Baek et al. 
2009). Under the transplantable tumor model, Ts65Dn mice also display significant 
decreases in tumor growth and microvessel density (Baek et al. 2009). Similar results were 
seen when using DSCR1-transgenic mice, suggesting that one extra copy of DSCR1 is 
sufficient for tumor growth suppression. Given that hChr21 contains over 200 genes, 
however, it is likely that other genes act in concert with DSCR1 to facilitate tumor 
suppressive effects. Another gene of interest includes Dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase (DYRK1A), a nuclear serine/threonine kinase located on 
hChr21. DYRK1A phosphorylates several transcription factors including NFAT. DYRK1A 
can therefore reduce Cn/NFAT-dependent transcription through its ability to export 
nuclear NFAT. Baek KH et al also show that endothelial cells overexpressing DSCR1 
together with DYRK1A demonstrate an even greater suppression of VEGF-mediated cell 
proliferation (Baek et al. 2009). Future work by Baek KH et al will focus on additional 
hChr21-located genes known to suppress tumor angiogenesis through alternate mechanisms 
(Ryeom, Baek & Zaslavsky, 2009), such as COLLAGEN XVIII (COL18A1), a precursor to the 
angiogenesis inhibitor endostatin, and ADAMTS1, a metalloproteinase known to regulate 
the anti-angiogeneic function of thrombospondin-1 (Iruela-Arispe, Carpizo & Luque, 2003; 
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Zaslavsky et al. 2010). In summary, the tumorigenic protective effects seen in DS adults may 
be due to increased expression of select hChr21-located genes, including DSCR1. 
4. Atherosclerosis in Down Syndrome 
Atherosclerosis progression is a complex process involving several cell types, multiple 
biological mechanisms, and environmental factors. The pathogenesis of atherosclerotic 
plaque formation is highly dependent on hemodynamic flow patterns (DeBakey, Lawrie & 
Glaeser, 1985; Vanderlaan, Reardon & Getz, 2004), thrombotic processes, and inflammatory 
signaling cascades (Lusis, 2000). Atherosclerosis is one of the leading causes of mortality in 
Westernized societies, and thus several cardiovascular risk factors have been identified over 
the last few decades in an effort to predict cardiovascular events. Given that atherosclerosis 
is characterized by accumulation of lipids in the large arteries, it is not surprising that 
elevated plasma triglyceride levels have been demonstrated as a direct propagator of 
cardiovascular disease (Austin, Hokanson & Edwards, 1998; Hokanson & Austin, 1996). 
Other plasma measurements indicative of cardiovascular risk include reduced levels of 
high-density lipoprotein (HDL) (Assmann et al. 1996; Gordon et al. 1977), and elevated 
serum levels of C-reactive protein (CRP), an indicator of inflammation (Mendall et al. 1996). 
High values for body mass index have also been demonstrated as a measure of 
cardiovascular risk (Berenson et al. 1998).  
Atherosclerotic cardiovascular disease has been associated with metabolic syndrome, which 
includes several clinical disorders such as obesity, insulin resistance, glucose intolerance, 
hypertension, and dyslipidemia (Moller & Kaufman, 2005). Consistent with the 
aforementioned metabolic deficiencies associated with DS patients, individuals with DS also 
exhibit impaired lipid metabolism (Ishihara et al. 2009). In addition, DS patients have lower 
levels of low-density lipoprotein receptor (LDLR) expression compared to adults without 
DS (Corsi et al. 2005). Interestingly, lack of or dysfunctional LDLR expression results in 
familial hypercholesterolemia, a genetic disease characterized by elevated cholesterol levels 
and premature coronary artery disease (Brown & Goldstein, 1976). LDLR-null mice have 
since been generated and is now a widely used atherosclerotic mouse model (Ishibashi et al. 
1993; Wouters et al. 2005). Lastly, DS patients exhibit significantly elevated levels of plasma 
triglycerides, low levels of HDL, high levels of CRP, and high levels of total body fat (Corsi 
et al. 2005; Draheim et al. 2010; Nishida et al. 1977). Taken together, these findings imply DS 
adults are surely at risk for cardiovascular events. DS patients, however, are significantly 
less susceptible to cardiovascular disease. A comparison of intimal-to-medial thickness 
(IMT) of the common carotid artery in DS adults show significantly lower IMT ratios when 
compared to control groups (Draheim et al. 2010). These findings corroborate the 
observational findings in 1977 where DS patients were proposed to be an “an atheroma-free 
model” (Murdoch et al. 1977). One can speculate that DS patients thus express an altered 
gene expression profile where an additional copy of hChr21-located genes results in 
protection against atheroma formation, despite the many validated plasma indicators of 
cardiovascular risk. Similar to the identified gene clusters responsible for the metabolic and 
developmental deficiencies in DS patients, it is highly likely that a cohort of genes located on 
hChr21 is responsible for the protective effects against cardiovascular disease. Identification 
of these genes will therefore provide a therapeutic direction as we continue to understand 
the etiology behind atherosclerotic plaque formation.  
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4.1 Vascular smooth muscle and atherogenesis 
At the cellular level, atherosclerosis progression is characterized by lipid accumulation and 
fibrous lesion formation in large arteries, resulting in chronic arterial wall inflammation. The 
release of cytokines and growth factors induce vascular smooth muscle cells (SMC) to 
undergo a process known as phenotypic modulation, whereby an adult, contractile SMC 
alters its expression profile to facilitate cell proliferation, migration, and/or inflammatory 
cell recruitment (Shin et al. 2008) (Figure 2). Phenotypic modulation is a key event 
underlying atherogenesis and in-stent restenosis that involves several signaling cascades, 
including the Cn/NFAT pathway. Activation of Cn/NFAT signaling has been shown to 
induce vascular SMC proliferation and migration in response to receptor tyrosine kinase 
and G-protein-coupled receptor agonists, respectively (Liu, Dronadula & Rao, 2004; 
Yellaturu et al. 2002). Cn/NFAT activity is also critical for vessel wall assembly (Graef et al. 
2001). Cyclosporin A (CsA) and the VIVIT peptide are commonly used Cn and NFAT 
inhibitors, respectively (Figure 1). A third pharmacological compound, A-285222, also 
inhibits Cn/NFAT signaling (Lee et al. 2010; Nilsson et al. 2007). Inhibition of Cn/NFAT 
signaling through use of either CsA or A-285222 attenuates Cn/NFAT-mediated SMC 
migration and proliferation in vitro (unpublished, Figure 1). Previous literature also shows 
that blocking Cn/NFAT signaling in vivo significantly inhibits vascular-injury-induced 
neointima formation (Liu et al. 2005), supporting the notion that Cn/NFAT signaling is 
intimately involved in the smooth muscle response to vascular injury. While NFAT-
dependent gene regulation has been widely studied in lymphocytes, cardiac and skeletal 
muscle, the lack of known NFAT target genes in SMCs limits our understanding of 
Cn/NFAT signaling in vascular remodeling. 
 
  
Fig. 2. The interplay between SMC phenotypic modulation and Cn/NFAT signaling in 
vascular disease. 
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4.2 Identification of DSCR1 using integrative genomics 
We recently developed an unbiased, top-down, integrative genomics approach to determine 
downstream targets of Cn/NFAT activation in vascular SMCs (Lee et al. 2010). In brief, 
whole-genome expression data sets were analyzed to identify differentially upregulated 
genes in human, mouse, and rat SMCs. Comparison between control and phenotypic 
modulatory stimuli identified 63 species-conserved, upregulated genes. Differentially 
upregulated genes were then compared against an in silico NFAT-ome (a list of gene 
promoters containing at least one species-conserved physical NFAT binding site), yielding 
18 potential Cn/NFAT-dependent genes. Use of pharmacological Cn/NFAT inhibitors 
substantiated the NFAT-dependent role for COX2, a previously identified Cn/NFAT 
dependent gene, and revealed the Cn/NFAT-dependent property of DSCR1 in vascular 
SMCs (Lee et al. 2010). DSCR1 has been reported in other cell types to function as a negative 
feedback regulator of Cn/NFAT signaling (Figure 1). Both gain- and loss-of-function studies 
were conducted to determine the role of DSCR1 in vascular SMCs. Overexpression of 
DSCR1 resulted in decreased NFAT transcriptional activity and reduced expression of other 
Cn/NFAT-dependent genes, such as COX2. Conversely, knockdown of endogenous DSCR1 
enhanced NFAT transcriptional activity suggesting DSCR1 also functions as a negative 
regulator in vascular SMCs (Lee et al. 2010). Lastly, analysis of in vivo whole-genome 
expression arrays found significant DSCR1 upregulation with acute vascular injury in 
mouse carotid arteries, regardless of strain type (Lee et al. 2010). The significant induction of 
DSCR1 exemplifies its functional importance and may be critical for modulating the 
vascular injury response. Similarly, an extra copy of the DSCR1 gene in DS patients may 
function in an atheroprotective manner through its ability to negatively regulate Cn/NFAT 
signaling. The recent study highlighting significantly less tumor growth in DSCR1-
transgenic mice (Baek et al. 2009) fosters the regulatory role of DSCR1 in Cn/NFAT-
mediated cell growth. It is possible DSCR1 functions in both endothelial cells and vascular 
SMCs as a modulator of cell proliferation, thereby providing a shared mechanism 
underlying tumorigenesis and atheroma formation. 
4.3 Ongoing research 
Several studies are currently underway in an effort to understand the functional role of 
DSCR1 in SMC phenotypic modulation and atherosclerotic plaque formation. DSCR1-
deficient mice have since been obtained and are proving to be instrumental as we continue 
to elucidate the role of DSCR1 in atherogenesis. DSCR1-related family members, however, 
have been identified in most eukaryotic organisms. In humans, DSCR1 family members 
include DSCR1-like 1 (DSCR1L1/ZAKI-4/RCAN2) and DSCR1-like 2 (DSCR1L2/RCAN3) 
(Strippoli et al. 2000). Interestingly, DSCR1L1 mimics the inhibitory effects of DSCR1 on Cn 
signaling in endothelial cells and inhibits angiogenesis (Gollogly, Ryeom & Yoon, 2007). In 
lymphocytes, DSCR1L2 blocks nuclear NFAT translocation and inhibits NFAT-dependent 
cytokine gene expression (Mulero et al. 2007). Given the functional overlap between the 
DSCR1 family members, global DSCR1-/- mouse models may possibly exhibit 
compensation by DSCR1L1 and/or DSCR1L2. In addition, DSCR1 plays a critical role in 
each of the major cell types seen with atherogenesis and will therefore be difficult to 
attribute our findings as a vascular SMC-specific response. Until a SMC-specific conditional 
knock-out mouse study is carried out, a conservative approach must be taken when 
interpreting results gathered from DSCR1-null mice given the complexities surrounding 
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DSCR1 expression and regulation in other cell types. Nonetheless, the data gathered will 
provide a better understanding of DSCR1 function. 
Apolipoprotein E (ApoE) is critical for lipoprotein metabolism. Defects in ApoE expression 
can consequently increase plasma cholesterol and triglyceride levels. Hence, targeted 
mutagenesis of the ApoE gene in mice promotes elevated serum cholesterol levels, where 
combination with a high fat/cholesterol diet results in massive accumulation of cholesterol 
and causative atherosclerotic lesion formation. DSCR1-/-; ApoE-/--double knockout mice 
have been generated in an effort to study how the absence of DSCR1 affects atherosclerotic 
plaque formation. These double-null mice have been placed on a 20-week, high 
fat/cholesterol diet to ensure plaque formation, where atherosclerotic plaque size will be 
quantified and compared against proper control groups. Given the literature to date, we 
predict atherosclerotic lesion formation and size to significantly increase in DSCR1-/-; ApoE-
/- double-null mice. The absence of DSCR1, a negative regulator of Cn/NFAT activity, 
should in theory promote SMC proliferation and infiltration into the neointima. A recent 
publication, however, emphasizes the dual role of DSCR1, suggesting DSCR1 is necessary 
for both Cn/NFAT activation and self-regulation (Liu, Busby & Molkentin, 2009). This effect 
has been demonstrated in cardiomyocytes and hypertrophy, an adaptive response driven by 
Cn and NFATc4 signaling (De Windt et al. 2001; Molkentin et al. 1998). Several groups have 
shown an attenuation of cardiac hypertrophy with overexpression of DSCR1 (Rothermel et 
al. 2001). DSCR1-/-; DSCR1L1-/- double-null mice were thus hypothesized to demonstrate 
significantly greater cardiac hypertrophy. DSCR1-/-; DSCR1L1-/- double-null mice, however, 
exhibit the reverse response – cardiac hypertrophy is impaired in response to adrenergic 
stimulation or exercise, similar to responses seen in calcineurin Aβ-/- mice (Sanna et al. 
2006). These results suggest a basal level of DSCR1 is necessary to properly activate 
Cn/NFAT signaling. The DSCR1 yeast homolog, RCN1/CBP1, has also been functionally 
characterized as a facilitator of Cn/NFAT signaling (Kingsbury & Cunningham, 2000). The 
notion that DSCR1 may also activate Cn/NFAT signaling highlights the elaborate nature of 
this protein, suggesting that the paradoxical function of DSCR1 depends on initial protein 
concentrations (Shin et al. 2006). It is thus possible we may instead observe a decrease in 
atherosclerotic lesion formation in the DSCR1-/-; ApoE-/- double-null mice. With this in 
mind, we have also placed DSCR1+/-; ApoE-/- mice to observe how DSCR1 
haploinsufficiency affects plaque formation. The presence of one DSCR1 allele will allow for 
minimal DSCR1 expression, yet also test the effects of reduced DSCR1 expression on lesion 
formation.  
We are also performing several in vitro assays on primary aortic SMC cultures from DSCR1-
/- mice to determine the consequences of DSCR1 absence on cell functionality. With our 
recent findings demonstrating DSCR1 as a negative regulator of Cn/NFAT signaling in 
vascular SMCs (Lee et al. 2010), one would hypothesize that DSCR1-null vascular SMCs to 
exhibit increased cell proliferation in response to phenotypic modulatory stimuli. 
Preliminary data, however, show a reduced proliferative response in DSCR1-null vascular 
SMCs when stimulated with either platelet-derived growth factor (PDGF-BB) or serum 
(unpublished). These initial results support the emerging dual role of DSCR1, suggesting 
basal levels of DSCR1 is necessary for Cn/NFAT activation. While our model cannot fully 
explain the almost complete absence of atheroma formation in DS patients, our results will 
not only help elucidate the functional role of DSCR1 in atherogenesis, but also provide 
insight on the effects of trisomy 21 through a single gene approach. 
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5. Vascular tone and Down Syndrome 
Enzyme activity of endothelial nitric oxide synthase (eNOS) plays a critical role in 
determining vascular tone through its ability to generate nitric oxide (NO) and consequently 
affect vascular smooth muscle contraction. Regulation of eNOS enzymatic activity is a 
highly dynamic system involving several kinases and phosphatases with significant 
downstream effects on NO-signaling (Duran, Breslin & Sanchez, 2010). While 
phosphorylation of eNOS is typically associated with enzyme activation, several groups 
demonstrate that dephosphorylation of eNOS can also trigger eNOS activation and 
subsequent NO production (Harris et al. 2001; Kou, Greif & Michel, 2002; Thomas, Chen & 
Keaney, Jr., 2002). The Cn phosphatase has been shown to target several proteins aside from 
NFAT, including eNOS (Kou et al. 2002). While the absolute role of DSCR1 is unknown in 
the vasculature, recent literature suggests DSCR1 plays a vital role in vessel contraction. 
DSCR1-/- mice have been reported to exhibit an attenuated vasocontriction response with 
phenylephrine treatment compared to appropriate controls (Riper et al. 2008). Riper DV et al 
speculate that the altered vascular constriction in DSCR1-/- mice may be due to Cn 
dysregulation, thereby facilitating excess endothelial NO production. Based on the proposed 
mechanism, overexpression of DSCR1 should then limit NO formation and promote 
vasoconstriction. As stated earlier, however, adults with DS are significantly hypotensive 
when compared to control groups (Morrison et al. 1996; Richards & Enver, 1979). Although 
the attenuated vasoconstriction response in DSCR1-/- mice may contradict the hypertensive 
nature of DS patients, the account by Riper DV et al is the first publication to date revealing 
a potential role of DSCR1 in vascular tone.  
It is also important to note that these observations of a weakened vasoconstriction response 
in DSCR1-/- mice reflect those of mesenteric rather than carotid arteries. While the 
underlying effects of NO on smooth muscle and vascular tone may be synonymous between 
the differing vascular beds, vasoconstriction could be regulated through different 
mechanisms. The effect of vascular bed type is further exemplified by the fact that while DS 
patients may be significantly hypotensive, they are also at an increased risk of developing 
pulmonary arterial hypertension (PAH) (Cua et al. 2007). The observed increase in PAH 
incidence amongst DS individuals may be due to several factors such as chronic upper 
airway obstruction (Jacobs, Gray & Todd, 1996) and abnormal pulmonary vasculature 
growth (Chi, 1975). Vascular tone therefore appears to depend not only on the vascular bed 
of interest but also on peripheral influences. In addition, basal levels of DSCR1 may be 
required for proper Cn/NFAT function, as previously described. Future contractility studies 
in haploinsufficient DSCR1+/- mice may thus provide clarity on the true role of DSCR1 in 
vascular tone. This study clearly demonstrates the widespread effect of DSCR1 loss, where 
dysregulation of Cn/NFAT activity in the endothelium alters paracrine signaling molecule 
production, creating invariable effects on neighboring cell types. The prevalent nature of 
DSCR1 prompts consideration for cell-cell interaction effects as we continue to decipher 
DSCR1 function in vascular disease. 
6. NFAT regulation and other considerations 
The importance of calcium signaling, NFATc transcriptional regulation, and ensuing 
downstream gene expression is increasingly evident. Adequate and controlled Cn/NFAT 
signaling is necessary, as dysregulation results in several vascular pathologies. Both the 
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versatility in DNA binding and the presence of multiple NFAT family members suggest 
NFAT proteins have a more extensive role than originally anticipated. A few notable 
features of NFAT are brought to attention below. 
NFAT transcription factors bind to DNA in a rather versatile manner. The promiscuous 
nature of NFAT-DNA binding suggests the presence of other binding partners. The most 
common and well-documented binding partner of NFAT is AP-1, a transcription factor 
comprised of Fos- and Jun- family proteins (Rao, Luo & Hogan, 1997). Several groups have 
demonstrated the need for cooperative NFAT-AP1 binding for optimal target gene 
transcription (Hogan et al. 2003). In addition to AP-1, NFAT has been shown to interact with 
other transcription factors involved in cell growth and differentiation, including GATA4, 
MEF2, and FOXP3 (Crabtree & Olson, 2002; Wu et al. 2006). Several groups have also noted 
the presence of multiple NFAT binding sites in validated NFAT-target gene promoters, such 
as interleukin-2 (Randak et al. 1990), interleukin-4 (Chuvpilo et al. 1993), and DSCR1 (Harris, 
Ermak & Davies, 2005). These multiple NFAT binding domains most likely confer a 
synergistic effect between NFAT-containing complexes and thereby promote efficient gene 
transcription (Rao et al. 1997). Thus, NFAT proteins may serve as ‘coincidence detectors’ 
(Crabtree & Olson, 2002) that can integrate information from multiple signaling pathways to 
coordinate gene expression.  
The ubiquitous nature of NFAT amongst various cell types and processes demonstrates the 
broad-range effects of NFAT activity. While functional redundancy has been noted between 
the different NFAT isoforms, differences in tissue distribution (Rao et al. 1997), evidence of 
multiple splice variants, and distinguishing phenotypes of NFAT-deficient mice suggest 
NFAT proteins may in fact possess unique isoform-specific functions. For example, while 
NFATc1 and NFATc2 share 72% sequence agreement and demonstrate functional similarities, 
genetic deletion for either NFATc isoform results in divergent mouse phenotypes. Whereas 
NFATc2-/- mice are viable and demonstrate an enhanced immune response (Duque, Fresno & 
Iniguez, 2005a), NFATc1-/- mice display abnormal cardiac valve development and consequent 
embryonic lethality (de la Pompa et al. 1998). Variations between NFAT proteins is further 
seen where targeted disruption of NFATc3, but not NFATc4, significantly reduces Cn 
transgene-induced cardiac hypertrophy (Wilkins et al. 2002). The disparate outcomes from 
NFATc genetic deletions as well as the ability for NFATc isoforms to compensate one another 
limits the use of NFATc-specific knock-out mice.  
Recent data have also challenged the longstanding premise viewing NFAT as a 
transcriptional activator. Several groups have in fact demonstrated the dual role of NFAT as 
both a gene activator and silencer (Robbs et al. 2008). NFATc1 and NFATc2 have been 
shown to repress cyclin-dependent kinase 4 (Horsley et al. 2008) and cyclinA2 (Carvalho et 
al. 2007) expression, respectively. NFATc2 has also been demonstrated as a negative 
regulator of cyclin B1 and cyclin E in lymphocytes (Caetano et al. 2002). The nonoverlapping 
functions and apparent gene silencing effects of individual NFATc proteins further 
complicates our understanding of Cn/NFAT signaling. NFAT is clearly involved in 
maintaining a balance between cell quiescence and cell proliferation – the two fundamental 
biological mechanisms underlying tumorigenesis and atherosclerosis.  
7. Conclusions 
The Cn/NFAT signaling cascade is undoubtedly a major determinant of cell growth and 
differentiation. Regulation of Cn/NFAT signaling is a critical determinant of neoplastic and 
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cardiovascular risk. With DSCR1 now known as an endogenous regulator of Cn/NFAT 
signaling, several groups have successfully manipulated downstream gene expression and 
cell function by altering DSCR1 levels. The observation that DS patients exhibit significantly 
less tumor growth and arterial plaque formation cannot be mere coincidence, but rather 
evidence supporting the notion that these large-scale, vascular-related pathologies share an 
underlying mechanism. This is further reinforced by the fact that DSCR1 and other 
candidate antiangiogenic genes found on hChr21 are of growing attention. A more 
comprehensive analysis of hChr21-located genes may therefore provide direction as we 
continue to elucidate the mechanisms underlying tumorigenesis and atherosclerotic plaque 
formation.  
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